IVVD Earnings Date: Nov 5, 2026 (Estimated) — Invivyd, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IVVD's next earnings date?
Invivyd, Inc. (IVVD) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11 on revenue of $15.0M.
How did IVVD do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Invivyd, Inc. posted EPS of -$0.14 versus the -$0.11 estimate, a miss of 0.0%. Revenue was $14.3M against a $14.4M estimate. The stock's 1-day post-earnings move was +5.1%.
How much does IVVD stock move after earnings?
IVVD beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.8% (up or down) in the day after earnings.
About Invivyd, Inc.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.11 | -0.14 | +0.00% | $14.3M | ❌ Miss | +5.13% | +38.66% | +30.06% |
| 2026-05-14 | Q1 2026 | -0.08 | -0.13 | -62.50% | $13.7M | ❌ Miss | -21.09% | -25.85% | -47.62% |
| 2026-03-05 | Q4 2025 | -0.08 | 0.02 | +125.00% | $17.2M | ✅ Beat | +1.75% | +11.11% | -25.15% |
| 2025-11-06 | Q3 2025 | -0.08 | -0.06 | +25.00% | $13.1M | ✅ Beat | +1.32% | +16.45% | +46.71% |
| 2025-08-14 | Q2 2025 | -0.01 | -0.12 | -1100.00% | $11.8M | ❌ Miss | -11.54% | -33.95% | +60.14% |
| 2025-03-20 | Q4 2024 | -0.33 | -0.15 | +54.55% | $13.8M | ✅ Beat | +2.58% | -14.51% | -29.17% |
| 2024-11-14 | Q3 2024 | -0.35 | -0.51 | -45.71% | $9.3M | ❌ Miss | -11.18% | -13.70% | -38.54% |
| 2024-08-14 | Q2 2024 | -0.36 | -0.40 | -11.11% | $2.3M | ❌ Miss | -7.55% | -18.59% | +8.49% |
Showing last 8 quarters.